Biopure corporation case pdf

Biopure strategy analysis essay 1760 words bartleby. Biopure corporation case study solution case study analysis. Biopure corporation case study richard addington phd table of contents 1. Case study solution, this is the beginning of 1998 and biopure corporation, a small biopharmaceutical company, not sales revenue in its tenyear history, has just received gove. Dba biopure healing products is not a medical facility. Bpur between march 17, 2003 and december 24, 2003, inclusive the class period. Biopure corporation, founded in 1984, privately owned.

Biopure corporation is a company that produces artificial blood substitutes that are used in humans and animals. Biopure corporation have two new products that are oxyglobin and hemopure. Decision sheet biopure corporation marketing objective whether to launch oxyglobin now or delay it till the approval of hemopure. Biopure case case study solution case study analysis. In litigation brought by the securities and exchange commission sec against biopure corporation biopure and several current and former officers of the company involving its drug hemopure, counsel for biopure retained cornerstone research to work with professor paul gompers of harvard business school. Through a link to a thirdparty content provider, this corporate website provides free access to biopures annual reports on form. Oxyglobin is the first new blood substitute for the veterinary market and is ready for consumer use. Biopure maintains a website at the following internet address. A quantitative way for deciding the pricing and the distribution strategy for oxyglobin. Jul 26, 2019 biopure corporation case pdf it is early and biopure corp. Come browse our large digital warehouse of free sample essays. Consequently the company soon has to further develop oxyglobin, strengthen its unique characteristics, while ensuring the quality of the product, to move away from potential competitors.

Biopure corporation case solution,biopure corporation case analysis, biopure corporation case study solution, introduction biopure corporation was founded in the year 1984. Biopure corporation, which was founded in 1984 by entrepreneurs carl rausch and david judelson, is a privately owned biopharmaceutical firm specializing in the ultra purification of proteins for human and veterinary use. Bioure, a delaware corporation, is a biopharmaceutical company with headquarters in cambridge, massachusetts. We do not have any medical staff on board, nor do we provide any medical advice on any of our products, which are intended to be used under the close supervision and care of a licensed medical professional. Exbiopure head settles sec blood substitute case law360. Hemopure is another new blood substitute for the human market and will take two years to launch. Biopure corporation has two new products that are oxyglobin and hemopure. Biopures primary goal was the development of a human blood substitute and its entry into the animal market was somewhat. Biopure corporation seeks compassionate use protocol for treatment of acute anemia read this article along with other careers information, tips and advice on biospace. Biopure products waste management products for every industry. Oxyglobin is the first blood substitute for the veterinary market and is ready for launch. Biopure case analysis biopurecaseanalysis analysis. Ted jacobs, vp human clinical trials, is concerned about.

Pgp14258 alok kumar pgp14279 lokesh singh pgp14280 mahtaab kajla pgp14283 naveen vyas pgp14303 shruti kabdal pgp. In conclusion, since the fda approval for human blood substitute is still uncertain, biopure should immediately launch oxyglobin. Oxyglobin and hemopure are two blood substitutes that biopure corporation was developing. A virtually identical product for the human market, hemopure, is in the final stages of testing by. Human market hemopure veterinary market oxyglobin oxyglobin already received final fda approval and is ready for launch hemopure. Hemopure is another new blood substitute for the human market and it will. Biopure corporation, a small firm in the bio pharmaceutical industry is facing challenges regarding the decision of launching a new product oxyglobin.

Financial projections sensitivity analysis 15 executive summary in 1998, biopure corporation is one of the three legitimate contenders in the emerging field of blood substitutes. Annual report pursuant to section or 15d of the securities exchange act of 1934 for the nscal year ended october 31, 2002 or n transition report pursuant to section or 15d of the securities exchange act of 1934 for the transition period from to. A quantitative way for deciding the pricing and the distribution strategy for oxyglobin note. In addressing the issue, the following were considered. Their findings showed the biopure mtad was more effective than the other solutions, and was retained in the root canal dentin for at least 28 days. Biopure s common stock is registered under section 12g of the exchange act and trades on the nasdaq stock exchange under the symbol bpur. Biopure corporation case solution and analysis, hbr case study. The company has been a privately owned pharmaceutical firm. Such waste is often found in barns and animal stalls, composting piles, septic systems, and many other places where biopure can be used. Buy biopure core highly bioavailable minerals and vitamins 240 vegetarian capsules on free shipping on qualified orders. Biopure corp1 free download as powerpoint presentation. In 1998 biopure pioneered the development of oxygen therapeutics using. Biopure hx2 system intended use canada this device is intended to remove organic, inorganic, and microbial contaminants from water that is used to dilute dialysis concentrate to form dialysate, and to produce purified water for dialyzer reprocessing and equipment rinse and sterilization.

Our formulas contain natural, raw ingredients that have been traditionally used to support overall health and wellbeing for centuries. The antibacterial efficacy of biopure mtad in root canal. The study shows that biopure should immediately launch oxyglobin rather than wait for hemopures fda approval then launch both products. Copyright 2019 home members home premium content links entities about streetinsider. Exacerbating the problem is the nature of the biopharmaceutical industry, where product approval is never a certainty until achieved. Biopure corporation writeup upload market segmentation.

However, this note will be of interest to any student who is interested in knowing how to employ a rigorous way of computing the price and the subsequent. Biopure corporation case writeup page 1 background analysis biopure corporation biopure was founded in 1984 with the. In 1998 biopure pioneered the development of oxygen therapeutics using hemoglobin, a new class of. Defer the launch of oxyglobin now till hemopure release. We recommend that biopure corporation should launch oxyglobin immediately, and not wait for the fda approval for hemopure, for the following reasons. Jul 02, 2019 biopure corporation case pdf it is early and biopure corp. Biopure corporation case solution and analysis, hbr case. Biopure final free download as powerpoint presentation. Biopure case analysis biopurecaseanalysis analysis launch. Indian institute of management kozhikode marketing management case analysis. Biopures common stock is registered under section 12g of the exchange act and trades on the nasdaq stock exchange under the symbol bpur.

Get the knowledge you need in order to pass your classes and more. Biopure corporation case pdf it is early and biopure corp. A case study biopure corporation specializes in blood substitutes for transfusion patients, both in the veterinary market and the human market. Biopure corporation case analysis situation analysis oxyglobin and hemobpure were biopures entries in the field of blood substitutes, hemopure targeting the human market and oxyglobin target at the animal market. A securities class action has been commenced on behalf of shareholders who purchased, converted, exchanged or otherwise acquired the common stock of biopure corporation nasdaq. Currently their product for animals, oxyglobin, has passed fda approval and can begin selling. Unlike cleaners that use chemicals andor enzymes to flush the lines, biopure, uses microbes to soak the system and eat away digest the organic waste in the lines, pipes, traps, filters and amalgam separator. Biopure corporation seeks compassionate use protocol for. Business case biopure brenda leeneman lilian van donk marit van barreveld simone huygens background biopure enters the field of blood substitutes. These findings are consistent with our own results group c and those of other researchers 15, 16, 2932 who have reported the superior efficacy of biopure mtad against e. Please use this form to contact us for any general inquiries.

However, in 1998, biopure faced the monumental decision of whether to begin selling oxyglobin, a blood substitute, to the veterinary market or to wait until. If yes, then devise a marketing plan for oxyglobin. Biopure corporation was a biopharmaceutical company that specialized in oxygen therapeutics blood substitutes for both human and veterinary use. Biopure case analysis sizing the market for hemopure analysis launch not launch first mover advantage build brand reputation generate revenue raise perception for ipo gain experience in the market may affect pricing for hemopure jeopardize legitimacy potential sizing the market page 5 vet practices 15,000 dogs 800 % dog transfusion 2. Commission file number 00115167 biopure corporation. Biopure corporation case analysis situation analysis oxyglobin and hemobpure were biopures entries in the field of blood substitutes, hemopure targeting the. Biopure has essentially one product, an oxygen therapeutic derived from bovine. Welcome to biopure we are committed to supplying healthcare practitioners and their patients with potent, highquality nutritional supplements. Jan 12, 2004 a securities class action has been commenced on behalf of shareholders who purchased, converted, exchanged or otherwise acquired the common stock of biopure corporation nasdaq. Biopure technology announces biovalve variable flow control valve. Our trading activity with organic products is certified by the austria bio garantie. May 27, 1999 biopure corporation it was february 5, 1998, as carl rausch, president and ceo of biopure corporation, opened his boston globe and read about the u.

Odors at home and on the ranch are caused by the bacteria living on decomposing organic waste. Biopure corporation, thomas moore, howard richman, and jane kober. Biopure corporation case study solution case study. Estimation of veterinary market and per year 14 exhibit 4. Biopure corporation class a news, biopure corporation. A virtually identical product for the human market, hemopure, is in the final stages of testing by biopure and is expected to gain approval within one to two years. The company developed, manufactured, and marketed oxygen therapeutics, designed to transport oxygen to the bodys tissues. Free forex prices, toplists, indices and lots more. Currently their product for animals, oxyglobin, has passed fda approval and can begin selling but the human product hemopure is still in phase 3 trials. Biopure final strategic management business economics.